Please login to the form below

Not currently logged in

Avastin hope in advanced ovarian cancer

Genentech's Avastin in combination with chemotherapy shows increase in advanced ovarian cancer PFS rate compared to chemotherapy alone

Genentech (part of the Roche Group) has announced positive results from a phase III trial involving Avastin. Data showed that Avastin in combination with chemotherapy followed by maintenance use of Avastin alone increased the progression-free survival (PFS) rate in women with previously untreated advanced ovarian cancer, compared to chemotherapy alone. 

The randomised, three-arm study involved women with newly diagnosed advanced ovarian cancer who had already received surgery to remove as much of the tumour as possible.

"This is good news for women with ovarian, primary peritoneal or fallopian tube cancers," said study chair Dr Robert Burger, Fox-Chase Cancer Center in Philadelphia.

Dr Hal Barron, executive vice president, global development and chief medical officer said: "We are encouraged by the positive findings of this study, which highlight the importance of continuing maintenance use of Avastin after combining Avastin with chemotherapy in this setting. We will discuss these results with the US Food and Drug Administration."

The National Cancer Institute (NCI) is sponsoring the trial under a cooperative research and development agreement between the NCI and Genentech. The trial is being conducted by a network of researchers led by the Gynecologic Oncology Group.

There are currently more than 450 clinical trials worldwide involving Avastin for the treatment of multiple types of cancer.

25th February 2010


Featured jobs

Subscribe to our email news alerts


Add my company

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?